Web of Science: 18 cites, Scopus: 17 cites, Google Scholar: cites
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
Bonanno, Laura (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy)
Costa Ribalta, Carlota (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Sanchez, Jose-Javier (Universidad Autónoma de Madrid)
Rodriguez, Ignacio (Universitat Autònoma de Barcelona. Institut Universitari Dexeus)
Gimenez-Capitan, Ana (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain)
Molina-Vila, Miquel Angel (Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain)
Vergnenegre, Alain (Hospital du Cluzeau, 23, rue Larey, Limoges, France)
Massuti, Bartomeu (Hospital General Universitari d'Alacant)
Favaretto, Adolfo (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy)
Rugge, Massimo (Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy)
Pallares, Cinta (Institut d'Investigació Biomèdica Sant Pau)
Taron, Miquel (Universitat Autònoma de Barcelona. Institut Universitari Dexeus)
Rosell, Rafael (Universitat Autònoma de Barcelona. Institut Universitari Dexeus)
Universitat Autònoma de Barcelona

Data: 2016
Resum: BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model. We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point. The median progression-free survival of all 71 patients was 7. 2 months whereas the median overall survival of the study population was 10. 7 months. Among patients with low BRCA1 expression, the median PFS was 7. 4 months in the presence of low HERC2 levels and 5. 9 months for patients expressing high HERC2 levels (p = 0. 01). The median OS was 15. 3 months for patients expressing low levels of both genes and 7. 4 months for those with low BRCA1 but high HERC2 (p = 0. 008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0. 03) and of death (p = 0. 004). These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model. The online version of this article (doi:10. 1186/s12885-016-2339-5) contains supplementary material, which is available to authorized users.
Nota: Altres ajuts: Work in Dr. Rafael Rosell's laboratory was partially supported by a grant from "La Caixa Foundation".
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: BRCA1 ; HERC2 ; Non-small-cell lung cancer ; Platinum ; Predictive markers ; DNA repair
Publicat a: BMC Cancer, Vol. 16 (may 2016) , ISSN 1471-2407

DOI: 10.1186/s12885-016-2339-5
PMID: 27179511


6 p, 538.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació Biomèdica Sant Pau
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-02-07, darrera modificació el 2022-01-02



   Favorit i Compartir